Learn

The early detection of adverse events following immunisation (AEFI) is essential to protect public health and to maintain confidence in vaccination. Vaccine pharmacovigilance — the monitoring, detection, investigation and actioning of vaccine safety signals — occurs across a collaborative landscape that includes the Therapeutic Goods Administration (TGA), the nationally funded surveillance initiative AusVaxSafety, and state and territory health departments.

The purpose of these pharmacovigilance systems is to monitor for unexpected types and rates of AEFI, including rare and population‐specific events. The identification and investigation of potential safety concerns is a key function of these systems, with the TGA also focused on ensuring that vaccines registered for use in Australia maintain a favourable benefit–risk profile.

This MJA Perspective shares more.

Details

Authors: Megan O'Moore, Belinda Jones, Megan Hickie, Catherine Glover, Lucy Deng, Yuanfei Huang, Michael Dymock, Evelyn Tay, Julie A Marsh and Nicholas Wood

Article Type: Perspective